News & Events
Jefferson Asthma Study Featured in Journal of Biological Chemistry
Researchers show how a new class of molecules could offer hope for people who suffer from asthma.
Jefferson Neurologist Wins Prestigious NASA Innovation Award
Professor George Brainard, Ph.D., Director of the Light Research Program at Thomas Jefferson University has been selected to receive NASA’s prestigious Johnson Space Center Director’s Innovation Award.
Jefferson Appoints Sandra Dayaratna, M.D., as Division Director of the Generalist Division of the Obstetrics & Gynecology Department
Department of Obstetrics and Gynecology, Sidney Kimmel Medical College announced the appointment of Sandra Dayaratna, M.D., as Clinical Associate Professor and Director of the Division of General Obstetrics and Gynecology.
Hold Your Breath to Protect Your Heart
A simple technique may be most effective in preventing heart disease after radiation therapy for breast cancer.
ESPN Features Jefferson Cardiologist Dr. Reggie Ho on 30for30
Dr. Ho balanced a pre-med academic schedule with football practice as a walk-on kicker.
How Does Prostate Cancer Form?
Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate the formation are poorly understood. Finding an enzyme that regulates this process could provide excellent new prevention approaches.
Unpacking Brain Damage in ALS
A new study published online today (December 17th) in the Cell Press journal Neuron shows that a common gene mutation in ALS generates a deadly protein that may cause the damage in the brain that leads to ALS.
Jefferson Named Best Radiologic Technologist Training Program
At the RSNA’s 100th annual meeting in Chicago in December, the Department of Radiologic Sciences in Jefferson’s School of Health Professions, received top honors as Best Radiologic Technologist Training Program.
HIV Drug Blocks Bone Metastases in Prostate Cancer
Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online December 1st in the journal Cancer Research, researchers show that the receptor CCR5 best known for its role in HIV therapy may also be involved in driving the spread of prostate cancer to the bone.